Lyell Immunopharma, Inc.
48 articles with Lyell Immunopharma, Inc.
-
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
-
Lyell Immunopharma announced this week that it has completed construction of a $65 million, 70,000-square-foot LyFE Manufacturing Center, which the company will use to support clinical trials and meet cell therapy manufacturing needs.
-
Lyell Immunopharma Announces Completion of LyFE Manufacturing Center
3/23/2021
Lyell Immunopharma, Inc. (Lyell), an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, today announced the completion of its $65 million LyFE Manufacturing Center in Bothell, Washington.
-
Lyell Appoints Richard Sherry, M.D., as Senior Vice President, TIL Specialist and Clinical Lead
3/16/2021
Lyell Immunopharma, Inc., an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, announced the appointment of Richard Sherry, M.D., as Senior Vice President, TIL Specialist and Clinical Lead.
-
BioSpace Movers & Shakers, Feb. 12
2/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Lyell Immunopharma Appoints Charlie Newton as Chief Financial Officer
2/9/2021
Lyell Immunopharma ("Lyell"), an immuno-oncology company dedicated to the mastery of T cells to cure solid tumors, today announced the appointment of Charlie Newton as Chief Financial Officer.
-
Orca Bio and Lyell Immunopharma Announce Research Partnership
9/2/2020
Orca Bio and Lyell Immunopharma today announced a research partnership to jointly identify next generation T cell therapies that will combine precision purification T cell technologies from Orca Bio with the scientific expertise in T cell biology from Lyell
-
Sarah Cannon and Lyell Immunopharma Announce Collaboration to Advance Development and Patient Access to T-Cell Therapies
8/27/2020
Sarah Cannon, the Cancer Institute of HCA Healthcare, and Lyell Immunopharma announced a strategic collaboration for the advancement of oncology-focused immune-effector, or T-Cell, therapies.